2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer

Clinical Infectious Diseases

Volumn 34, Issue 6, 2002, Pages 730-751

  Hughes, Walter T ^a   Armstrong, Donald ^b   Bodey, Gerald P ^c   Bow, Eric J ^g   Brown, Arthur E ^b   Calandra, Thierry ⁱ   Feld, Ronald ^h   Pizzo, Philip A ^d,e   Rolston, Kenneth V I ^c   Shenep, Jerry L ^a   Young, Lowell S ^f  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Kuzell Institute for Arthritis and Infectious Diseases   (United States)

^g UNIVERSITY OF MANITOBA   (Canada)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CISPLATIN; COLONY STIMULATING FACTOR; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; TOBRAMYCIN; UREIDOPENICILLIN; VANCOMYCIN;

ALGORITHM; ANTIBIOTIC THERAPY; CANCER PATIENT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; GRANULOCYTE TRANSFUSION; HUMAN; HYPOKALEMIA; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MONOTHERAPY; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

ANTI-INFECTIVE AGENTS; DRUG THERAPY; EVALUATION STUDIES; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA;

EID: 0037087226     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/339215     Document Type: Review

References (191)

1. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
2. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
3. Empiric antibiotic therapy for granulocytopenic cancer patients
4. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis
5. Chronic neutropenia
6. Clinical presentation of infection in granulocytopenic patients
7. Guidelines for the management of intravascular catheter-related infection
8. Current blood culture methods and systems: Clinical concepts, technology, and interpretation of results
9. Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward
10. Clinical correlations of serial quantitative blood cultures determined by lysis-centrifugation in patients with persistent septicemia
11. Is quantitative variation in cancer patients with bacteremic infections linked to severity of infection?
12. Controlled comparison of BacT/ALERT FAN aerobic medium and VATEC fungal blood culture medium for detection of fungemia
13. Controlled evaluation of 5 versus 10 milliliters of blood cultured in aerobic BacT/Alert blood culture bottles
14. Atypical mycobacterial infections of Hickman catheter exit sites
15. Systemic candidiasis
16. Practice guidelines for the management of infectious diarrhea
17. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem cell transplant recipients: Use of high resolution computed tomography
18. The value of skin biopsies in febrile, neutropenic, immunocompromised children
19. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fcγ receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia
20. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: Comparison with interleukin-8
21. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: Targeting empirical monotherapy versus combination therapy
22. An analysis of interleukin-8, interleukin-6, and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia, and complicated infection in neutropenic cancer patients
23. Bacteremia due to viridans streptococci in neutropenic patients: A review
24. Treatment of gram-positive septicemia in cancer patients
25. Pseudomonas aeruginosa - Still a frequent pathogen in patients with cancer: 11-Year experience at a comprehensive cancer center
26. Prospective study of bacteremia in cancer patients
27. Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients
28. Febrile neutropenia in cancer patients in Kuwait: Microbial spectrum and outcome
29. Postoperative bacteremia in cancer patients with solid tumors undergoing surgery: Risk factors, etiology and outcome in 276 patients
30. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients
31. Diagnosis of venous access port-related infections
32. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures
33. Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 Cases and review
34. An approach to the design and implementation of clinical trails of empirical antibiotic therapy in febrile and neutropenic cancer patients
35. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients
36. β-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy
37. Randomized trial of betalactam regimens in febrile neutropenic cancer patients
38. Beta-lactam regimens for the febrile neutropenic patient
39. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial
40. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients
41. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial
42. New trends in patient management: Risk-based therapy for febrile patients with neutropenia
43. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
44. Early discharge of low-risk febrile neutropenic children and adolescents with cancer
45. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
46. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia
47. Predicting the risk of bacteremia in children with fever and neutropenia
48. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition
49. Outcome of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials
50. The multinational association for supportive care in cancer risk index: A multinational scoring system for identify, low-risk febrile neutropenic cancer patients
51. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule
52. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer
53. Oral administration of cefixime to lower risk febrile neutropenic children with cancer
54. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections
55. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone
56. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial
57. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia
58. Home treatment of febrile neutropenia: An empirical oral antibiotic regimen
59. Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients
60. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients
61. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia: CEMIC
62. Empiric monotherapy for febrile neutropenia - A randomized study comparing meropenem with ceftazidime
63. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients
64. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenia patients: A prospective randomized pilot study
65. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia
66. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: A randomized, single-center phase II trail
67. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients
68. Is monotherapy for febrile neutropenia still a viable alternative?
69. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: A prospective randomized multicentre trial in patients without previous prophylactic antibiotics
70. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients
71. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
72. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?
73. A randomized trial of cefepime vs. ceftazidime as initial therapy for patients with prolonged fever and neutropenia after intensive chemotherapy
74. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: A randomized, double-blind trial
75. Reduction in vancomycin consumption in patients with fever and neutropenia
76. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic patients
77. High dose intravenous ciprofloxacin in febrile neutropenic patients
78. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients
79. Randomized, double-blind multicenter trail comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients
80. Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients
81. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumor
82. Effects of the combination of gentamicin and carbenicillin on the bactericidal activity of serum
83. Empirical therapy for febrile, neutropenic patients: Persistence of susceptibility of gram-negative bacilli to aminoglycoside antibiotics
84. Bacterial resistance in the patient with neoplastic disease
85. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia
86. Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers
87. In-vitro activity of moxifloxacin against gram-negative isolates from cancer patients
88. In vitro activity of gatifloxacin against gram-negative isolates from cancer patients
89. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor
90. Ciprofloxacin/piperacillin vs. tobramycin/piperacillin as empiric therapy for fever in neutropenic cancer patients, a randomized, double-blind trial
91. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes
92. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HIC-PAC)
93. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: Pros and cons
94. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer
95. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors
96. In vitro additive effect of imipenem combined with vancomycin against multiple-drug resistant, coagulase-negative staphylococci
97. Ciprofloxacin/vancomycin (C/V) as initial empiric therapy in febrile neutropenic leukemia/lymphoma patients (pts) with indwelling venous access devices: Preliminary results of an effective regimen with reduced hospital stay
98. Aztreonam plus vancomycin versus gentamicin plus piperacillin as empirical therapy for the treatment of fever in neutropenic patients: A randomized controlled study
99. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients
100. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: A randomized prospective study
101. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients
102. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial
103. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer
104. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer
105. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients
106. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: Effect on cyclosporin-associated nephrotoxicity
107. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
108. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients
109. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer
110. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients
111. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones
112. Time to clinical response: An outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care
113. Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient
114. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition
115. Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital
116. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: A prospective study
117. Cell-wall deficient bacteria and culture-negative febrile episodes in bone marrow recipients
118. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
119. Empiric antifungal therapy in febrile granulocytopenic patients
120. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
121. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin lipid complex in the empirical treatment of febrile neutropenia
122. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia
123. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients
124. A multi-center randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
125. A systematic review of the efficacy of azoles and lipid-based formulations of amphotericin B as empirical antifungal therapy in persistently febrile neutropenic patients despite broad-spectrum antibacterial therapy
126. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial
127. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer
128. Post-sepsis prophylaxis in cancer patients
129. Antibiotic therapy in febrile neutropenic patients: What is the optimum duration of therapy?
130. Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination
131. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia
132. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients?
133. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin
134. Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia
135. Early detection of pneumonia in febrile neutropenic patients: Use of thin-section CT
136. Computed tomography of hepatic and splenic fungal abscesses in leukemic children
137. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients
138. Persistent fever after recovery from granulocytopenia in acute leukemia
139. Antibiotic resistant fever associated with herpes simplex virus infection in neutropenic patients with haematological malignancy
140. Granulocyte transfusions: Efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation
141. Combined treatment with amphotericin B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation
142. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study
143. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases
144. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double blind placebo-controlled study in children
145. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia
146. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever
147. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic chemotherapy regimens: Results of a randomized phase III trial
148. Filgrastim in patients with chemotherapy-induced febrile neutropeniam - A double-blind, placebo-controlled trial
149. Randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy related febrile neutropenia
150. Role of granulocyte colony-stimulating factor as adjunct therapy for septicemia in children with acute leukemia
151. Clinical benefits and cost savings of interventional G-CSF therapy in patients with febrile neutropenia following chemotherapy
152. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors
153. Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients
154. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma
155. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies
156. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines
157. Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants
158. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis
159. Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patient with lymphoma
160. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis
161. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer - Is it justified?
162. Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia
163. Quinolone-based chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity
164. Bacteremia due to methicillin-resistant staphylococci occurs more frequently in neutropenia patients who received antimicrobial prophylaxis and is associated with higher mortality in comparison of methicillin-sensitive bacteremia
165. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer: A trial of oral penicillin V or placebo combined with pefloxacin
166. Prophylaxis with fluoroquinolones in neutropenic patients: A meta-analysis
167. Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: A meta-analysis
168. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin
169. Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients
170. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center
171. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia
172. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
173. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients
174. Candidemia in allogenic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
175. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
176. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic patients: Benefit based on purpose and intensity of cytotoxic therapy
177. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients - Recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Transplantation
178. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial
179. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients
180. Antifungal prophylaxis in neutropenic patients: A meta-analysis of randomized-controlled trials
181. Outpatient management of febrile, neutropenic patients
182. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule
183. Stopping antibiotic therapy in neutropenic patients
184. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics
185. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer
186. Antibiotic treatment of febrile episodes in neutropenic cancer patients: Clinical and economic considerations
187. Current attitudes for therapy for febrile neutropenia with consideration to cost-effectiveness
188. A randomized dosage study of ceftazidime with single daily tobramycin for the empirical management of febrile neutropenia in patients with hematological diseases
189. Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia
190. Assessing the effectiveness of disease and injury prevention programs: Costs and consequences